Logo Prima Biomed


Welcome to the Newsroom

05 June 2017

LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial


  • Breast cancer clinical trial demonstrates LAG-3Ig (IMP321) is safe and well tolerated
  • Data shows IMP321 in combination with chemotherapy leads to a sustainable increase in antigen presenting cells (APC), CD8 T cells and an improved pre-dose Th1 status
  • Encouraging activity with a disease control rate of 87%